-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 E0GkNZzKR+XJGVwRMxY4xjXnr6AWj+6zQUAWZKUSmP30INoWaj7cZDu1yJdcq/hW
 Pb9OTKynmk/q8n1xSxaoMQ==

<SEC-DOCUMENT>0000200406-04-000073.txt : 20040426
<SEC-HEADER>0000200406-04-000073.hdr.sgml : 20040426
<ACCEPTANCE-DATETIME>20040423175023
ACCESSION NUMBER:		0000200406-04-000073
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20040422
ITEM INFORMATION:		Other events
ITEM INFORMATION:		Financial statements and exhibits
FILED AS OF DATE:		20040426

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			JOHNSON & JOHNSON
		CENTRAL INDEX KEY:			0000200406
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				221024240
		STATE OF INCORPORATION:			NJ
		FISCAL YEAR END:			0103

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-03215
		FILM NUMBER:		04752185

	BUSINESS ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933
		BUSINESS PHONE:		7325242454
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>eightkapriltwentytwo.txt
<TEXT>


               SECURITIES AND EXCHANGE COMMISSION
                     Washington, D.C. 20549


                            FORM 8K

       Current Report Pursuant to Section 13 or 15(d) of
              The Securities Exchange Act of 1934



  Date of Report (Date of earliest event reported): April 13, 2004


                        JOHNSON & JOHNSON

     (Exact name of registrant as specified in its charter)


    New Jersey                1-3215              22-1024240

(State or other             Commission        (I.R.S. Employer
jurisdiction                File Number)      Identification No.)
of incorporation)



 One Johnson & Johnson Plaza, New Brunswick, New Jersey   08933

           (Address of principal executive offices)    (zip code)


Registrant's telephone number including area code: (732) 524-0400


Item 5. Other Events

On April 22, 2004, Johnson & Johnson announced its intent to
increase its quarterly dividend by 18.8 percent beginning in June
2004.  A copy of the press release is furnished as Exhibit 99
to this report and is incorporated herein by reference.

Item 7.  Financial Statements and Exhibits

     7(c)      Exhibits:

     Exhibit Number 99: Johnson & Johnson Press Release dated
April 22, 2004




                            SIGNATURE



Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned hereunto duly authorized.



                                   JOHNSON & JOHNSON




Date: April 23, 2004          By: /s/Stephen J. Cosgrove
                                   Stephen J. Cosgrove
                                  Chief Accounting Officer




</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>3
<FILENAME>exhibitninetynine.txt
<TEXT>
   JOHNSON & JOHNSON ANNOUNCES DIVIDEND INCREASE OF 18.8%

Dividend Increase of 18.8 Percent Announced by Johnson &
Johnson

New Brunswick, NJ (April 22, 2004) - Johnson & Johnson today
announced that its Board of Directors has declared an 18.8
percent increase in the quarterly dividend rate, from $.24
cents per share to $.285 cents per share. The increase was
announced this morning at the Annual Shareholders Meeting in
New Brunswick, NJ.

"In recognition of our outstanding results in 2003, our very
strong financial position and our confidence in the future
of the corporation, the Board has voted to increase our
dividend for the 42nd consecutive year," said William C.
Weldon, Chairman and Chief Executive Officer of the Company.

At the new rate, the indicated dividend on an annual basis
is $1.14 compared to the previous rate of $.96. The next
quarterly dividend is payable on June 8, 2004 to
shareholders of record as of May 18, 2004.

On April 13, Johnson & Johnson announced record sales and
earnings for the first quarter of 2004. Sales of $11.6
billion and net earnings of $2.5 billion increased by 17.7
percent and 20.4 percent, respectively, over 2003 first
quarter results.

Johnson & Johnson, with approximately 109,500 employees, is
the world's most comprehensive and broadly based
manufacturer of health care products, as well as a provider
of related services, for the consumer, pharmaceutical and
medical devices and diagnostics markets. Johnson & Johnson
has more than 200 operating companies in 57 countries,
selling products throughout the world.


</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
